Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
NurExone Biologic: Technisches (täglich, wöchentlich, monatlich) & Analysten "Strong Buy"-Rating!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
25 Leser
Artikel bewerten:
(0)

Clinical Study Initiations, Stock Price Updates, and Strategic Agreements - Analyst Notes on Ariad, Jazz Pharma, Intercept, Community Health, and United Technologies

NEW YORK, April 2, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Community Health Systems, Inc. (NYSE: CYH), and United Technologies Corporation (NYSE: UTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Ariad Pharmaceuticals Inc. Analyst Notes

On March 24, 2014, Ariad Pharmaceuticals Inc. (Ariad) announced the commencement of a pivotal global Phase II trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. According to Ariad, the ALTA (ALK in Lung Cancer Trial of AP26113) trial, designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who test positive for the anaplastic lymphoma kinase (ALK+) oncogene, will have primary endpoint as objective response rate (ORR) which is measured by RECIST criteria. Secondary endpoints include time to response, duration of response, disease control rate, progression-free survival, overall survival, safety, and tolerability. The full analyst notes on Ariad Pharmaceuticals Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04022014/ARIA/report.pdf

--

Jazz Pharmaceuticals Plc Analyst Notes

On March 28, 2014, the stock of Jazz Pharmaceuticals Plc (Jazz) ended lower by 3.29% at $133.46, amidst rumors in some sections of the media that the Company is willing to pay $20-plus a share to acquire oncology-focused Ariad Pharmaceuticals Inc. After opening at $136.86, the stock oscillated in the range of $131.51 - $137.95, with a total of 1.22 million shares changing hands. Over the past 12 months, the stock has increased by 138.71%, significantly outperforming the Dow Jones Industrial Average which rose 11.97% during the same period. The full analyst notes on Jazz Pharmaceuticals Plc are available to download free of charge at:

http://www.AnalystsReview.com/04020214/JAZZ/report.pdf

--

Intercept Pharmaceuticals Inc. Analyst Notes

On March 28, 2014, the stock of Intercept Pharmaceuticals Inc. (Intercept) resumed its southward journey after a brief relief and ended the session lower by 3.47% at $317.58. The stock opened at $326.48 and traded in the range of $313.14 - $335.98, with a total volume of 0.50 million shares. The stock, which quadrupled in just one day on January 9, 2014 on positive clinical trial results, has declined 18.76% in last five trading sessions, which the analysts attribute to profit booking in the overall biotechnology sector. The NASDAQ Biotechnology index has slipped 7.02% in last five trading sessions. The full analyst notes on Intercept Pharmaceuticals Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04022014/ICPT/report.pdf

--

Community Health Systems, Inc. Analyst Notes

On March 19, 2014, Community Health Systems, Inc. (CHS) announced that a subsidiary of the Company has entered into a definitive agreement to lease 421-bed Munroe Regional Medical Center in Ocala, Florida, for a period of 40 years, starting Q2 2014. According to the Company, the agreement also provides for the creation of a clinical affiliation between Munroe Regional Medical Center and UF Health Shands, which will hold a minority equity position in the hospital operating company. Commenting on the development, Wayne T. Smith, Chairman and CEO of CHS, said, "We are very pleased to move forward in this relationship and look forward to working with the medical staff and employees of Munroe Regional in support of the quality care they provide for their community. We also look forward to the contributions UF Health Shands will bring to Munroe Regional and to the benefits of clinical affiliation with an academic healthcare leader in Florida." The full analyst notes on Community Health Systems, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04022014/CYH/report.pdf

--

United Technologies Corporation Analyst Notes

On March 28, 2014, the stock of United Technologies Corporation (UTC) closed at $114.81, up 0.89% from its previous day's close. After opening at $114.20, the stock oscillated in the range of $114.12 - $115.44. During the session, a total of 2.46 million shares were traded, which was lower than its 30-day average daily volume of 3.38 million. The stock has gained 22.88% in last 12 months, outperforming the Dow Jones Industrial Average which rose 11.97% during the same period. The full analyst notes on United Technologies Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04022014/UTX/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

SOURCE Analysts Review

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.